OSR Holdings shares are trading lower after the company announced a license agreement for its VXM01 immunotherapy that includes up to $815 million in milestone payments.
benzinga_article
OSR Holdings shares are trading lower after the company announced a license agreement for its VXM01 immunotherapy that includes up to $815 million in milestone payments.
